Ποια είναι η τιμή για KemPharm, Inc. (KMPH)

Η τιμή για KemPharm, Inc. (KMPH) είναι $5.81

Ποια είναι η κεφαλαιοποίηση αγοράς για KemPharm, Inc. (KMPH)

Η κεφαλαιοποίηση αγοράς για KemPharm, Inc. (KMPH) είναι $200.14M

KemPharm, Inc. (KMPH) Τιμή και Κεφαλαιοποίηση Αγοράς

KemPharm, Inc. operates as a specialized pharmaceutical firm focused on discovering and advancing proprietary prodrugs to tackle serious medical conditions across the United States. The company employs its innovative Ligand Activated Therapy (LAT) platform to create improved prodrug versions of medications already approved by the FDA, and also to develop prodrugs from existing compounds for potential applications in new disease indications. Its pipeline of investigational prodrugs strategically targets high-need areas such as attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) disorders, including idiopathic hypersomnia (IH). KP1077, KemPharm's leading experimental compound, is a prodrug of d-methylphenidate, known as serdexmethylphnidate, and is currently in Phase II clinical trials for the treatment of IH and narcolepsy. Additionally, the company is advancing KP879, a prodrug candidate designed to treat stimulant use disorder, which is undergoing Phase I clinical evaluation. KemPharm has also obtained FDA approval for AZSTARYS, a new once-daily ADHD treatment for patients aged six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company holds collaboration and license agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Founded in 2006, KemPharm, Inc. is headquartered in Celebration, Florida.

Η τιμή για KMPH	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$157,467 $200.14M	NVDA	$5.424T	+2,710,172.77%
$138,644 $200.14M	AAPL	$4.776T	+2,386,194.05%
$117,624 $200.14M	GOOG	$4.052T	+2,024,407.26%
$107,151 $200.14M	MSFT	$3.691T	+1,844,144.48%
$79,665.21 $200.14M	AMZN	$2.744T	+1,371,073.95%

Η τιμή για KMPH

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$157,467 $200.14M